Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RLMD Relmada Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RLMD
Price (delayed)
$0.6785
Market cap
$22.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.51
Enterprise value
$21.37M
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed
Highlights
Relmada Therapeutics's net income has increased by 20% YoY and by 5% QoQ
The EPS has grown by 20% YoY and by 5% from the previous quarter
The quick ratio has contracted by 24% YoY but it has grown by 19% from the previous quarter
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.relmada.com
Key stats
What are the main financial stats of RLMD
Market
Valuations
Earnings
Shares outstanding
33.19M
Market cap
$22.52M
Enterprise value
$21.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$79.12M
Net income
-$75.71M
EBIT
-$75.71M
EBITDA
-$75.71M
Free cash flow
-$56.79M
Per share
Balance sheet
Liquidity
EPS
-$2.51
EPS diluted
-$2.51
Free cash flow per share
-$1.87
Book value per share
$0.68
Revenue per share
$0
TBVPS
$0.91
Total assets
$27.68M
Total liabilities
$5.24M
Debt
$0
Equity
$22.44M
Working capital
$22.43M
Debt to equity
0
Current ratio
5.29
Quick ratio
5.17
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-151.2%
Return on equity
-181.3%
Return on invested capital
-191%
Return on capital employed
-337.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLMD stock price
How has the Relmada Therapeutics stock price performed over time
Intraday
-3.06%
1 week
-3.1%
1 month
13.65%
1 year
-77.68%
YTD
30.48%
QTD
151.3%
Financial performance
How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$79.12M
Net income
-$75.71M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's net income has increased by 20% YoY and by 5% QoQ
Relmada Therapeutics's operating income has increased by 20% YoY and by 6% from the previous quarter
Price vs fundamentals
How does RLMD's price correlate with its fundamentals
Growth
What is Relmada Therapeutics's growth rate over time
Valuation
What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 20% YoY and by 5% from the previous quarter
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
The P/B is 67% less than the 5-year quarterly average of 3.0 and 9% less than the last 4 quarters average of 1.1
Efficiency
How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has shrunk by 78% YoY and by 23% QoQ
RLMD's return on invested capital has dropped by 74% year-on-year and by 24% since the previous quarter
The ROA has dropped by 66% year-on-year and by 21% since the previous quarter
Dividends
What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLMD.
Financial health
How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has shrunk by 67% YoY and by 40% QoQ
RLMD's total liabilities has shrunk by 58% YoY and by 49% QoQ
RLMD's debt is 100% smaller than its equity
RLMD's equity has plunged by 69% YoY and by 37% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.